HRP940464A2 - The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases - Google Patents

The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases Download PDF

Info

Publication number: HRP940464A2
Authority: HR; Croatia
Prior art keywords: flupirtine; fact; production; active substance; treats
Prior art date: 1993-08-17

Application number

HRP4327516.8A

Other languages

English (en)

Croatian (hr)

Inventor

Michael Schwarz

Gabriela Pergande

Jurgen Engel

Bernd Nickel

Heinz Ulrich

Stefan Szelenyi

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-17

Filing date

1994-08-16

Publication date

1997-06-30

1994-08-16 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1997-06-30 Publication of HRP940464A2 publication Critical patent/HRP940464A2/hr

Links

229960003667 flupirtine Drugs 0.000 title claims description 85
JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 title claims description 84
208000015122 neurodegenerative disease Diseases 0.000 title claims description 10
230000004770 neurodegeneration Effects 0.000 title claims description 8
230000000324 neuroprotective effect Effects 0.000 title 1
229940079593 drug Drugs 0.000 claims description 31
239000003814 drug Substances 0.000 claims description 31
239000013543 active substance Substances 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 17
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
230000002490 cerebral effect Effects 0.000 claims description 4
201000006474 Brain Ischemia Diseases 0.000 claims description 3
206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
230000036592 analgesia Effects 0.000 claims description 3
206010008118 cerebral infarction Diseases 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
230000002458 infectious effect Effects 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
231100000331 toxic Toxicity 0.000 claims description 3
230000002588 toxic effect Effects 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 2
201000001320 Atherosclerosis Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
230000000626 neurodegenerative effect Effects 0.000 claims description 2
239000003176 neuroleptic agent Substances 0.000 claims description 2
230000000701 neuroleptic effect Effects 0.000 claims description 2
210000001428 peripheral nervous system Anatomy 0.000 claims description 2
210000001525 retina Anatomy 0.000 claims description 2
206010010904 Convulsion Diseases 0.000 claims 1
206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 claims 1
208000030886 Traumatic Brain injury Diseases 0.000 claims 1
230000003412 degenerative effect Effects 0.000 claims 1
239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
208000023589 ischemic disease Diseases 0.000 claims 1
208000020431 spinal cord injury Diseases 0.000 claims 1
230000011514 reflex Effects 0.000 description 33
239000002904 solvent Substances 0.000 description 21
239000007924 injection Substances 0.000 description 20
238000002347 injection Methods 0.000 description 20
230000000694 effects Effects 0.000 description 19
238000007913 intrathecal administration Methods 0.000 description 14
238000000585 Mann–Whitney U test Methods 0.000 description 9
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 9
239000000126 substance Substances 0.000 description 9
230000002461 excitatory amino acid Effects 0.000 description 8
239000003257 excitatory amino acid Substances 0.000 description 8
230000009471 action Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000007928 intraperitoneal injection Substances 0.000 description 7
210000003205 muscle Anatomy 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 5
229960004381 flumazenil Drugs 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
230000002040 relaxant effect Effects 0.000 description 5
-1 2-amino-3-ethyl-ethoxycarbonylamino-6(5-fluoro-benzyl)-aminopyridine maleate Chemical group 0.000 description 4
208000014644 Brain disease Diseases 0.000 description 4
208000032274 Encephalopathy Diseases 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000000202 analgesic effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 4
229960001289 prazosin Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 3
241001132374 Asta Species 0.000 description 3
IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
241000458112 Nonarthra tibialis Species 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 3
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 3
AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
229940127240 opiate Drugs 0.000 description 3
230000036407 pain Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229960000317 yohimbine Drugs 0.000 description 3
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 3
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 2
206010036105 Polyneuropathy Diseases 0.000 description 2
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229960002802 bromocriptine Drugs 0.000 description 2
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000000994 depressogenic effect Effects 0.000 description 2
239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000005284 excitation Effects 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000007794 irritation Effects 0.000 description 2
229960003587 lisuride Drugs 0.000 description 2
238000000034 method Methods 0.000 description 2
ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
229960004851 pergolide Drugs 0.000 description 2
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000011160 research Methods 0.000 description 2
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
229960003946 selegiline Drugs 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
HKJKCPKPSSVUHY-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;iodide Chemical compound [I-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 HKJKCPKPSSVUHY-GRTNUQQKSA-M 0.000 description 1
RPRYDUZRUYYQGA-UHFFFAOYSA-N 2-amino-2-phosphonoheptanoic acid Chemical compound CCCCCC(N)(C(O)=O)P(O)(O)=O RPRYDUZRUYYQGA-UHFFFAOYSA-N 0.000 description 1
RWVIMCIPOAXUDG-UHFFFAOYSA-N 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C([N+]([O-])=O)=C2 RWVIMCIPOAXUDG-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 1
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000000572 bronchospasmolytic effect Effects 0.000 description 1
229960004205 carbidopa Drugs 0.000 description 1
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
229950009941 chloralose Drugs 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000001037 epileptic effect Effects 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229960001655 flupirtine maleate Drugs 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
PIPZGJSEDRMUAW-VJDCAHTMSA-N hydron;methyl (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate;chloride Chemical compound Cl.C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 PIPZGJSEDRMUAW-VJDCAHTMSA-N 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000000631 nonopiate Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
208000019629 polyneuritis Diseases 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000002972 tibial nerve Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
229960000488 tizanidine Drugs 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
229960000949 yohimbine hydrochloride Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Confectionery (AREA)

HRP4327516.8A 1993-08-17 1994-08-16 The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases HRP940464A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4327516A DE4327516A1 (de)	1993-08-17	1993-08-17	Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Publications (1)

Publication Number	Publication Date
HRP940464A2 true HRP940464A2 (en)	1997-06-30

Family

ID=6495312

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HRP4327516.8A HRP940464A2 (en)	1993-08-17	1994-08-16	The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases

Country Status (27)

Country	Link
US (1)	US5721258A (ja)
EP (1)	EP0716602B1 (ja)
JP (1)	JPH09501664A (ja)
KR (1)	KR100341952B1 (ja)
CN (1)	CN1086291C (ja)
AT (1)	ATE210442T1 (ja)
AU (1)	AU694447B2 (ja)
BG (1)	BG62430B1 (ja)
BR (1)	BR9407293A (ja)
CA (1)	CA2169718C (ja)
CZ (1)	CZ289040B6 (ja)
DE (2)	DE4327516A1 (ja)
DK (1)	DK0716602T3 (ja)
EE (1)	EE03204B1 (ja)
ES (1)	ES2168309T3 (ja)
HR (1)	HRP940464A2 (ja)
HU (1)	HU227765B1 (ja)
IL (1)	IL110681A (ja)
NO (1)	NO309842B1 (ja)
NZ (1)	NZ273292A (ja)
PT (1)	PT716602E (ja)
RU (1)	RU2166318C2 (ja)
SK (1)	SK283330B6 (ja)
UA (1)	UA43351C2 (ja)
WO (1)	WO1995005175A1 (ja)
YU (1)	YU49215B (ja)
ZA (1)	ZA946176B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19539861A1 (de) *	1995-10-26	1997-04-30	Asta Medica Ag	Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) *	1995-11-07	1997-05-15	Asta Medica Ag	Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) *	1996-06-27	1998-01-02	Asta Medica Ag	Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
EP1034783B1 (en) *	1997-10-27	2004-12-15	Sumitomo Pharmaceuticals Company, Limited	Amide derivatives for the treatment of retinal neurodegenerative disorders
AU1359801A (en) *	1999-11-05	2001-06-06	Vela Pharmaceuticals Inc.	Methods and compositions for treating reward deficiency syndrome
US6821995B1 (en)	1999-12-01	2004-11-23	Duke University	Method of treating batten disease
WO2001039760A2 (en) *	1999-12-01	2001-06-07	Duke University	Method of treating batten disease
DE10327674A1 (de) *	2003-06-20	2005-01-05	Awd.Pharma Gmbh & Co. Kg	Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) *	2003-06-23	2005-01-27	Schmidt, K.-G., Dr. med.	Flupirtine-Präparat
EP1701725B1 (en) *	2003-12-16	2013-07-31	Relevare Aust. Pty Ltd	Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain
US20080287399A1 (en) *	2004-12-14	2008-11-20	Astrazeneca Ab	Substituted Aminopyridines and Uses Thereof
EP1688141A1 (en)	2005-01-31	2006-08-09	elbion AG	The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) *	2005-05-16	2006-11-16	Andrulis Peter J Jr	Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) *	2007-05-07	2008-11-13	Bernd Terhaag	Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de)	2010-03-31	2011-10-06	Awd.Pharma Gmbh & Co. Kg	Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de)	2010-06-14	2011-12-15	Awd.Pharma Gmbh & Co.Kg	Injizierbare Darreichungsform von Flupirtin
WO2015017565A1 (en) *	2013-07-31	2015-02-05	Teva Pharmaceutical Industries Ltd.	Treatment of multiple sclerosis with combination of laquinimod and flupirtine
WO2019014547A1 (en) *	2017-07-14	2019-01-17	Texas Tech University System	FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
DE102017007385A1 (de)	2017-08-02	2019-02-07	Christoph Hoock	Maleatfreie feste Arzneimittelformen
CN120346203B (zh) *	2025-06-23	2026-01-09	西安交通大学	GluK1受体激动剂在制备治疗慢性疼痛的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4481205A (en) *	1980-09-13	1984-11-06	Degussa Aktiengesellschaft	2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
DE3337593A1 (de) *	1982-10-27	1984-05-03	Degussa Ag, 6000 Frankfurt	2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
ATE25078T1 (de) *	1982-10-27	1987-02-15	Degussa	2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
NO860825L (no) *	1985-03-23	1986-09-24	Degussa	Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
EP0517852B1 (en) *	1990-03-02	2002-07-10	STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of	Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
IN172468B (ja) *	1990-07-14	1993-08-14	Asta Medica Ag
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them

1993
- 1993-08-17 DE DE4327516A patent/DE4327516A1/de not_active Ceased
1994
- 1994-08-10 HU HU9600355A patent/HU227765B1/hu unknown
- 1994-08-10 PT PT94926828T patent/PT716602E/pt unknown
- 1994-08-10 RU RU96105707/14A patent/RU2166318C2/ru active
- 1994-08-10 US US08/602,742 patent/US5721258A/en not_active Expired - Lifetime
- 1994-08-10 DE DE69429435T patent/DE69429435T2/de not_active Expired - Lifetime
- 1994-08-10 CA CA002169718A patent/CA2169718C/en not_active Expired - Lifetime
- 1994-08-10 ES ES94926828T patent/ES2168309T3/es not_active Expired - Lifetime
- 1994-08-10 SK SK214-96A patent/SK283330B6/sk not_active IP Right Cessation
- 1994-08-10 WO PCT/EP1994/002649 patent/WO1995005175A1/en not_active Ceased
- 1994-08-10 DK DK94926828T patent/DK0716602T3/da active
- 1994-08-10 KR KR1019960700753A patent/KR100341952B1/ko not_active Expired - Lifetime
- 1994-08-10 CZ CZ1996465A patent/CZ289040B6/cs not_active IP Right Cessation
- 1994-08-10 CN CN94193106A patent/CN1086291C/zh not_active Expired - Lifetime
- 1994-08-10 NZ NZ273292A patent/NZ273292A/en not_active IP Right Cessation
- 1994-08-10 AT AT94926828T patent/ATE210442T1/de active
- 1994-08-10 EP EP94926828A patent/EP0716602B1/en not_active Expired - Lifetime
- 1994-08-10 BR BR9407293A patent/BR9407293A/pt not_active Application Discontinuation
- 1994-08-10 JP JP7506731A patent/JPH09501664A/ja active Pending
- 1994-08-10 AU AU76528/94A patent/AU694447B2/en not_active Expired
- 1994-08-15 YU YU51294A patent/YU49215B/sh unknown
- 1994-08-16 IL IL11068194A patent/IL110681A/xx not_active IP Right Cessation
- 1994-08-16 ZA ZA946176A patent/ZA946176B/xx unknown
- 1994-08-16 HR HRP4327516.8A patent/HRP940464A2/hr not_active Application Discontinuation
- 1994-10-08 UA UA96030972A patent/UA43351C2/uk unknown
- 1994-10-25 EE EE9400160A patent/EE03204B1/xx unknown
1996
- 1996-02-14 BG BG100356A patent/BG62430B1/bg unknown
- 1996-02-15 NO NO960607A patent/NO309842B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU227765B1 (en)	2012-02-28
UA43351C2 (uk)	2001-12-17
BR9407293A (pt)	1996-10-01
YU51294A (sh)	1998-05-15
NO309842B1 (no)	2001-04-09
NO960607L (no)	1996-02-15
EP0716602A1 (en)	1996-06-19
IL110681A0 (en)	1994-11-11
AU7652894A (en)	1995-03-14
YU49215B (sh)	2004-11-25
CA2169718A1 (en)	1995-02-23
US5721258A (en)	1998-02-24
BG100356A (bg)	1996-07-31
KR960703591A (ko)	1996-08-31
IL110681A (en)	1999-08-17
NZ273292A (en)	1999-09-29
SK21496A3 (en)	1997-01-08
EP0716602B1 (en)	2001-12-12
NO960607D0 (no)	1996-02-15
SK283330B6 (sk)	2003-06-03
RU2166318C2 (ru)	2001-05-10
ATE210442T1 (de)	2001-12-15
DE4327516A1 (de)	1995-02-23
PT716602E (pt)	2002-05-31
EE03204B1 (et)	1999-08-16
ES2168309T3 (es)	2002-06-16
DE69429435D1 (de)	2002-01-24
CZ46596A3 (en)	1996-05-15
WO1995005175A1 (en)	1995-02-23
KR100341952B1 (ko)	2003-04-11
DE69429435T2 (de)	2002-06-13
CN1129399A (zh)	1996-08-21
AU694447B2 (en)	1998-07-23
CZ289040B6 (cs)	2001-10-17
DK0716602T3 (da)	2002-03-25
BG62430B1 (bg)	1999-11-30
CA2169718C (en)	2002-11-12
ZA946176B (en)	1995-03-20
HUT75650A (en)	1997-05-28
JPH09501664A (ja)	1997-02-18
HU9600355D0 (en)	1996-04-29
CN1086291C (zh)	2002-06-19

Legal Events

Date	Code	Title	Description
1997-06-30	A1OB	Publication of a patent application
1997-11-05	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2002-08-16	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20020816 Year of fee payment: 9
2002-08-28	PNAN	Change of the applicant name, address/residence	Owner name: VIATRIS GMBH & CO.KG, DE
2002-08-28	PPPP	Transfer of rights	Owner name: ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG, DE
2002-09-04	ODBI	Application refused

Publication	Publication Date	Title
HRP940464A2 (en)	1997-06-30	The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases
US5256669A (en)	1993-10-26	Methods and compositions for treating acute or chronic pain and drug addiction
Lewis et al.	1997	Tramadol: a new centrally acting analgesic
US10517841B1 (en)	2019-12-31	Compositions and methods for treating respiratory depression with fenfluramine
KR20230141875A (ko)	2023-10-10	N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민
JP2013501805A (ja)	2013-01-17	脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JPH10505087A (ja)	1998-05-19	非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
CN105209445A (zh)	2015-12-30	治疗运动障碍和相关病症的方法
EP3773532A1 (en)	2021-02-17	Levodopa fractionated dose composition and use
CN106413714A (zh)	2017-02-15	(r)‑吡吲哚及其药学上可接受的盐的药学用途
JPH045231A (ja)	1992-01-09	慢性痛用鎮痛剤
JP7233741B2 (ja)	2023-03-07	炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
Waheed et al.	2022	Tramadol and its health implications
EA003557B1 (ru)	2003-06-26	Схема обезболивания
US11559525B2 (en)	2023-01-24	Therapeutic drug for dyskinesia
MX2014010237A (es)	2015-07-17	Uso del modafinilo en el tratamiento de cocainomanos.
CA3095341C (en)	2025-11-25	Levodopa fractionated dose composition and use
Edwards	1983	Systemic medications of use in pain treatment
Schafflera et al.	2004	Analgesic Effects of Low-dose Intravenous Orphenadrine in the State of Capsaicin Hyperalgesia.
Popoli et al.	1995	CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease
Salmasi et al.	1995	Influence of adenosine and ADP on expression of surface antigens of human T-lymphocytes is connected with stimulation of single type of purine receptors
Poli et al.	1995	Functional interactions between adenosine A1 and class II of metabotropic glutamate receptors in rat hippocampus